ArticleOncology letters2026
Pseudocirrhosis due to liver metastasis from lung squamous cell carcinoma: A case report.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudocirrhosis is extremely rare and primarily observed in metastatic breast cancer, with only a handful of cases involving other primary malignancies. Regarding lung cancer, only two cases of lung adenocarcinoma have been reported. To the best of our knowledge, no previous reports have described pseudocirrhosis associated with lung squamous cell carcinoma. The present study reports the case of a 74-year-old male who was diagnosed with primary squamous cell carcinoma in the left lower lobe of the lung. Computed tomography scans revealed multiple metastatic lesions in the liver. There was no history of liver disease. Treatment with an immune checkpoint inhibitor plus chemotherapy was initiated for four cycles, followed by maintenance therapy with the same immune checkpoint inhibitor. Although the pulmonary lesions and liver metastases showed marked regression, cirrhotic-like morphological changes developed in the liver 1 year later. Despite immediate discontinuation of the immune checkpoint inhibitor and aggressive treatment with human albumin infusion, liver protection and diuretics, the patient succumbed to liver failure. In conclusion, patients with liver metastases from lung squamous cell carcinoma may also present with pseudocirrhosis, and clinicians need to be aware of this presentation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.